Arca
Skip to content
Tools
Tools

TYK2: Non-receptor tyrosine-protein kinase TYK2

Non-membrane spanning protein tyrosine kinase involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity.

  • Drugs that act on it: 7
  • Approved: 4
  • In phases 1 to 3: 3
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on TYK2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 7

Approved4

  • Ruxolitinib
  • Upadacitinib
  • Filgotinib
  • Cravacitinib

Phase 31

  • Brepocitinib

Phase 22

  • Cerdulatinib
  • Ropsacitinib

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Damora Therapeutics114%
    • Dermavant Sciences GmbH114%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 6 of 7 act as: Tyrosine-protein kinase TYK2 inhibitor; the rest name their own mechanism.
    RuxolitinibBoxed warningApprovedDamora TherapeuticsSmall moleculeInhibitor194
    UpadacitinibBoxed warningApprovedAbbVieSmall moleculeInhibitor91
    FilgotinibApprovedAlfasigmaSmall moleculeInhibitor14
    CravacitinibApprovedBristol-Myers SquibbSmall moleculeNegative allosteric modulatorTyrosine-protein kinase TYK2 negative allosteric modulator0
    BrepocitinibPhase 3Priovant TherapeuticsSmall moleculeInhibitor3
    CerdulatinibPhase 2Dermavant Sciences GmbHSmall moleculeInhibitor0
    RopsacitinibPhase 2PfizerSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov.
    A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.UpadacitinibPhase 2 / Phase 3Not yet recruitingAbbVieNov 12, 2026
    Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational StudyRuxolitinib—Not yet recruitingAffiliated Hospital of Nantong UniversityNov 9, 2026
    A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)RuxolitinibPhase 1RecruitingMemorial Sloan Kettering Cancer CenterNov 3, 2026
    Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized VitiligoRuxolitinibNot applicableEnrolling by invitationKafrelsheikh UniversityNov 2, 2026
    ADBest TREAT RegistryUpadacitinib—RecruitingUniversitätsklinikum Hamburg-EppendorfOct 29, 2026
    Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid ArthritisUpadacitinibPhase 2Not yet recruitingAbbVieOct 29, 2026
    A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental VitiligoUpadacitinibPhase 3Not yet recruitingAbbVieOct 27, 2026
    A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other TherapiesUpadacitinib—Not yet recruitingPfizerOct 21, 2026
    A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsRuxolitinibPhase 1RecruitingDamora TherapeuticsSep 30, 2026
    A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersUpadacitinibPhase 1RecruitingAbbVieSep 28, 2026
    Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialRuxolitinibPhase 2Not yet recruitingUniversity Hospital, Basel, SwitzerlandSep 25, 2026
    Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With MyelofibrosisRuxolitinibPhase 1RecruitingHenan Cancer HospitalSep 3, 2026
    Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)RuxolitinibPhase 1Not yet recruitingChildren's Hospital Medical Center, CincinnatiSep 3, 2026
    Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNIRuxolitinibPhase 1 / Phase 2Not yet recruitingPeking University People's HospitalSep 1, 2026
    An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory UveitisUpadacitinibPhase 4Active, not recruitingTianjin Medical UniversityAug 19, 2026
    A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataUpadacitinibPhase 3RecruitingAbbVieAug 19, 2026
    FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled TrialFilgotinibPhase 4Not yet recruitingUniversity Hospital, Clermont-FerrandMay 8, 2026
    Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsFilgotinibPhase 3RecruitingAlfasigma S.p.A.Apr 28, 2026
    OLE Study With Filgotinib in JIAFilgotinibPhase 3RecruitingAlfasigma S.p.A.Apr 27, 2026
    A Phase 2/3 Study of Brepocitinib in Adults With Lichen PlanopilarisBrepocitinibPhase 2 / Phase 3RecruitingPriovant Therapeutics, Inc.Apr 16, 2026
    A Study of Brepocitinib in Adults With Cutaneous SarcoidosisBrepocitinibPhase 2 / Phase 3RecruitingPriovant Therapeutics, Inc.May 18, 2025
    A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical PracticeFilgotinibPhase 4Active, not recruitingEisai Korea Inc.May 9, 2025
    A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative ColitisFilgotinibPhase 3RecruitingAlfasigma S.p.A.Mar 7, 2025
    JAK Inhibitor Dose TAPering Strategy StudyFilgotinibPhase 4RecruitingUniversity Hospital, ToulouseNov 13, 2024
    A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisBrepocitinibPhase 3Active, not recruitingPriovant Therapeutics, Inc.May 28, 2024
    Drug Rediscovery for Rare Immune Mediated Inflammatory DiseasesFilgotinibPhase 2RecruitingUMC UtrechtFeb 29, 2024
    A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean ParticipantsFilgotinib—RecruitingEisai Korea Inc.Feb 7, 2024

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Immunodeficiency 35
    0.75
    Psoriasis vulgaris
    0.72
    Crohn disease
    0.69
    Atopic eczema
    0.59
    Type 1 diabetes mellitus
    0.58
    Hypothyroidism
    0.58

    Genes and related targets

    Complexes and families that share a gene with this target
    Genes
    TYK2

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3553, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P29597, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.